ライフサイエンスコーパス: OR

1 grelor versus clopidogrel (1.1% versus 1.0%; OR, 1.07; 95% CI 0.45-2.53) in patients >/=75 years old

2 ohort for these two populations, (P = 0.004, OR = 1.55).

3 nfidence interval (CI): 1.50, 8.23, p=0.004; OR=2.09; 95% CI: 1.27, 3.46, p=0.004, respectively] and

4 onsortium (N=60,586, meta-analysis P=0.0095, OR=1.05, and 95% CI=1.01-1.09).

5 dently of traditional risk factors (model-1, OR: 0.647, 95%CI: 0.495-0.846), and after additional adj

6 al mortality (odds ratio [OR], 2.1; P = 0.1; OR, 5, P = 0.05, respectively).

7 holinesterase; rs7609897-T: P=1.5 x 10(-10), OR=0.87) with diverticular disease and in FAM155A (famil

8 ) = 3.47 in Asians (Pmeta = 3.1 x 10(-104)), OR = 2.61 in European Americans, OR = 2.02 in African Am

9 ilarity 155A; rs67153654-A: P=3.0 x 10(-11), OR=0.82) with diverticulitis.

10 or in those <75 years old (0.4% versus 0.2%; OR, 2.24; 95% CI, 1.02-4.93; P [interaction]=0.21).

11 djustment for glycaemic parameters (model-2, OR: 0.670, 95%CI: 0.511-0.878).

12 e women without disabilities (11.0% vs 7.5%, OR 1.5; p=0.01).

13 5-7.2), rhinitis with patterns 1 to 4 and 6 (OR, 2.2-4.3), and eczema with patterns 1 to 3 and 5 to 7

14 and eczema with patterns 1 to 3 and 5 to 7 (OR, 1.6-2.5).

15 compared with clopidogrel-GPI (0.3% vs 0.7%; OR, 0.43; 95% CI, 0.11-1.66).

16 l neurological recovery (mRS 0-1) at day 90 (OR 7.6, 95% CI 1.6 to 37.2, p=0.010).

17 12-input expression (A1 AND A2 AND NOT A1*) OR (B1 AND B2 AND NOT B2*) OR (C1 AND C2) OR (D1 AND D2)

18 0.75), to report regular physical activity (OR, 0.37; 95% CI: 0.20, 0.70), or to have read the infor

19 itis (OR 3.51, P = .009), low visual acuity (OR 5.1, P = .001), high laser-flare (LF) values (OR 1.74

20 with a higher risk of NEC, with an adjusted OR of 2.3 (95% CI: 1.2, 4.5; P = 0.01) and 2.0 (95% CI:

21 te difference in mRS 0-2 of 22% and adjusted OR 4.9, 95% CI 1.2 to 19.7, p=0.021).

22 atopy and "any allergic condition" (adjusted OR AOR, 95% CI, 0.54; 0.32-0.92, P = .02, and .31; 0.10-

23 3.6% of cases and 1.1% of controls; adjusted OR, 4.00 [95% CI, 3.40-4.70]; clopidogrel and a VKA: 0.3

24 .3% of cases and 0.04% of controls; adjusted OR, 7.93 [95% CI, 4.49-14.02]).

25 associated with advanced fibrosis (adjusted OR, 1.044; P = 0.025).

26 ikely to use antenatal care (pooled adjusted OR 0.54 [0.42-0.71]) or to immunise their children (0.57

27 exception of daily tobacco smoking (adjusted OR 1.74, 95% CI 1.08-2.81), any illicit drug use (1.72,

28 cataract for long-term SSRI users (adjusted OR, 1.24; 95% CI, 1.15-1.34) compared with nonusers.

29 ancreatitis, compared to non-users, adjusted OR 0 .

30 igh dietary fat intake >/=37% (GG vs. AA/AG, OR 2.36 [1.02-5.49], p = 0.045).

31 5% CI, 1.40-1.55]; small for gestational age OR, 1.15 [95% CI, 1.06-1.25]; autism spectrum disorder h

32 52]) but not with small for gestational age (OR, 1.01 [95% CI, 0.81-1.25]), autism spectrum disorder

33 atio [OR], 7.21; P < 0.001) and greater age (OR, 1.05; P = 0.045) were associated with increased risk

34 ssociated with asthma up to 16 years of age (OR 1.31; 95% CI 1.08-1.59), while exposure to mold odor

35 Large index SPs alone (OR, 14.34; 95% CI, 5.03-40.86) or index STSA alone (OR,

36 34; 95% CI, 5.03-40.86) or index STSA alone (OR, 9.70; 95% CI, 3.63-25.92) significantly increased th

37 10(-104)), OR = 2.61 in European Americans, OR = 2.02 in African Americans) and other autoimmune dis

38 ty, with individuals in quartile 4 having an OR of 2.57 (95% CI: 1.75, 3.76) and 2.73 (95% CI: 1.88,

39 .68-1.32, p=0.745 for case-control analysis; OR=0.95, 95% CI 0.45-1.97, p=0.884 for propensity score

40 CRC risk [OR: 1.48 (95% CI: 1.08, 2.02) and OR: 1.50 (95% CI: 1.10, 2.04), respectively] for the fou

41 R, 1.09 per procedure; 95% CI, 1.03-1.14 and OR when exposure from >/=6 procedures: 2.58; 95% CI, 1.4

42 R, 1.10 per procedure; 95% CI, 1.05-1.16 and OR when exposure from >/=6 procedures, 3.08; 95% CI, 1.7

43 CD and UC (OR: 2.12; 95% CI: 1.33, 3.36 and OR: 1.61; 95% CI: 1.01, 2.57, respectively).These findin

44 .3 to 0.8 for </= 5-year life expectancy and OR, 0.4; 95% CI, 0.3 to 0.6 for </= 10-year life expecta

45 een shown to disrupt neuronal maturation and OR expression in the developing embryonic OE.

46 en (OR = 0.34, P = .002), and appendicolith (OR = 1.67, P = .02).

47 ted odds of serious ventricular arrhythmias (OR, 31.8; 95% CI, 4.3-236.3) and maternal in-hospital mo

48 uropean Americans) and rheumatoid arthritis (OR = 1.65 in Koreans).

49 risks were observed for nonallergic asthma (OR 1.80; 95% CI 1.27-2.55) and rhinitis (OR 1.41; 95% CI

50 D A2 AND NOT A1*) OR (B1 AND B2 AND NOT B2*) OR (C1 AND C2) OR (D1 AND D2) OR (E1 AND E2).

51 1; P = .007), parent recommendation to bank (OR, 12.30; 95% CI, 2.01 to 75.94; P = .007), and higher

52 r, 0.93-0.98; p<0.001) and clinical benefit (OR 0.95 per extra year, 0.92-0.98; p=0.004).

53 exposure was associated with preterm birth (OR, 1.34 [95% CI, 1.18-1.52]) but not with small for ges

54 Compared with whites, blacks (OR, 0.89; 95% CI, 0.86-0.92) and Latinos (OR, 0.83; 95%

55 5269 was identified as a risk factor of BPD (OR 1.8, p = 5.3 x 10(-5)), independently of the robust a

56 *) OR (B1 AND B2 AND NOT B2*) OR (C1 AND C2) OR (D1 AND D2) OR (E1 AND E2).

57 excluding most smoking-related cancer cases (OR, 1.10 per procedure; 95% CI, 1.05-1.16 and OR when ex

58 OR], 0.71; 95% CI, 0.50-1.00) and all-cause (OR, 0.50; 95% CI, 0.39-0.64) readmission rates vs childr

59 al Cancer Institute (NCI)-designated center (OR 1.70, CI 1.58-1.82).

60 than those treated in nonaggressive centers (OR, 1.73; 95% CI, 1.05-3.15).

61 70) following OAR as well as higher charges (OR, 1.28; 95% CI, 1.01-1.62) and increased 30-day readmi

62 ting the analysis to rituximab chemotherapy (OR = 0.19, 95% CI 0.11-0.32) and lymphoma (OR = 0.18, 95

63 nd was stronger in Black vs. White children (OR = 0.30, 95% CI: 0.15, 0.61 vs. OR = 0.78, 95% CI: 0.2

64 ry Sjogren's syndrome (OR = 2.45 in Chinese, OR = 2.35 in European Americans) and rheumatoid arthriti

65 es among the MESA Hispanic-Americans cohort (OR per triglyceride GRS unit: 2.04; 95% CI: 1.03 to 4.03

66 %)) patients allocated endovascular coiling (OR: 0.54 (0.13-1.90), p=0.40).

67 sk (37% frequent vs 45% abundant/continuous, OR, 1.64, P = .03 for difference; 8% rare/occasional vs

68 , 2.71, P = .03, vs 23% abundant/continuous, OR, 1.95, P = .04).

69 ytes, more often than their AA counterparts (OR 3.01 95% CI 1.38-6.57, P = 0.006).

70 al [CI] 1.51-5.03), people-oriented culture (OR=2.59, 95% CI 1.45-4.62), and ergonomic practices (OR=

71 was found for exposure to cyclophosphamide (OR, 3.58; 95% CI, 0.91-14.11) followed by mitoxantrone h

72 2 AND NOT B2*) OR (C1 AND C2) OR (D1 AND D2) OR (E1 AND E2).

73 0 [95% CI, 1.25-2.90]; I2 = 17%), and death (OR, 5.13 [95% CI, 1.50-17.57]; I2 = 55%).

74 independent predictor of in-hospital death (OR = 1.89, P = 0.014), even after adjusting for the Euro

75 OR: 5.50 [3.42-9.00] and atopic dermatitis: OR 3.76 [2.14-6.61]), and drug use (LABA + ICS: 1.86 [1.

76 .46, P < .0001), increased maximum diameter (OR = 1.29, P < .0001), simple periappendiceal fluid (OR

77 .37; 95% CI, 2.24-8.54), multigland disease (OR, 7.63; 95% CI, 3.49-16.69), multinodular goiter or th

78 6.72; 95% CI, 1.55-29.04; P = 0.01) and ECA (OR, 3.08; 95% CI, 1.37-6.94; P = 0.007) resulted in gran

79 (1.37-11.5), p = 0.01) and pre-treated eGFR (OR, 0.98 (0.95-1.00), p = 0.04).

80 es was associated with increasingly elevated ORs for unhealthy obesity, with individuals in quartile

81 Self-reported Asian ethnicity (OR = 0.51; CI, 0.39-0.65), needing assistance for at lea

82 ificant risk of major cardiovascular events (OR, 0.985 [95% CI, 0.955-1.015]).

83 mellar incision at the center of the eyelid (OR, 6.72; 95% CI, 1.55-29.04; P = 0.01) and ECA (OR, 3.0

84 ter adjustment for traditional risk factors (OR (95%CI) 3.68 (1.06-12.83) and 8.65 (2.46-30.49), resp

85 Baseline liver fat (OR 2.17; 95%CI: 1.05-4.46) was an independent predictor

86 3.16], history of atopic disease (hay fever: OR: 5.50 [3.42-9.00] and atopic dermatitis: OR 3.76 [2.1

87 8, P = .002), complex periappendiceal fluid (OR = 18.5, P < .0001), fluid-filled lumen (OR = 0.34, P

88 9, P < .0001), simple periappendiceal fluid (OR = 2.08, P = .002), complex periappendiceal fluid (OR

89 associated with high-level fluoroquinolone (OR, 3.99 [95% CI, 1.10 to 14.40]) and kanamycin (OR, 5.4

90 val (CI), 1.22-2.00]; P < 0.001) and 2-fold (OR = 2.00 [CI, 1.15-3.49]; P = 0.015), respectively.

91 ference; 8% rare/occasional vs 15% frequent, OR, 2.71, P = .03, vs 23% abundant/continuous, OR, 1.95,

92 = 3,670), but not intracerebral hemorrhage (OR [95% CI] = 0.97 [0.84-1.12]; p = 0.71; 1,545 cases, 1

93 insecticides and phenoxyacetate herbicides [OR=1.9 (95% CI: 1.2, 2.8)].

94 n those who did not report injecting heroin (OR 3.0, 95 % CI 1.3-7.3; p=0.01) or being in prison (OR

95 CI, 1.2-2.5), hospitalization status at HT (OR, 1.5; 95% CI, 1.0-2.19), chronic steroid use at HT (O

96 5% CI, 1.0-2.19), chronic steroid use at HT (OR, 1.5; 95% CI, 1.0-2.2), and treatment for early rejec

97 , 1.1-2.0), support with >/=inotropes at HT (OR, 1.7; 95% CI, 1.2-2.5), hospitalization status at HT

98 ted with the development of oligoanuric HUS (OR, 2.38 [95% CI, 1.30-4.35]; I2 = 2%), renal replacemen

99 st in subjects with LBW and HWC (+LBW/+HWC), OR 4.74 (95%CI, 1.48-15.21).

100 .11) followed by mitoxantrone hydrochloride (OR, 2.73; 95% CI, 0.23-33.0).

101 with cerebral white matter hyperintensities (OR [95% CI] = 1.10 [1.05-1.16]; p = 5.3 x 10(-5) ; N = 3

102 of RTT when compared with cemented implants (OR, 0.69; 95% CI, 0.54-0.88; P = .002) but for other typ

103 demonstrate that F-actin automata implement OR, AND, XOR and AND-NOT gates via interacting patterns

104 te level of experience showed improvement in OR performance score.

105 g fruit bats showed evidence of expansion in ORs, supporting a "trade-off" between sensory modalities

106 on usage and respiratory symptoms increased [OR=3.51; 95% confidence interval (CI): 1.50, 8.23, p=0.0

107 and scale them to four-input AND, six-input OR, and a complex 12-input expression (A1 AND A2 AND NOT

108 ites possessing commercial health insurance (OR = 2.98; 95% CI, 2.66-3.33).

109 y for estrogen receptor-positive disease (IQ-OR, 1.44; 95% CI, 1.16 to 1.79; P for heterogeneity = .1

110 ictive power was similar to the TC model (IQ-OR, 1.45; 95% CI, 1.21 to 1.73; mC, 0.55), but SNP88 was

111 overall (interquartile range odds ratio [IQ-OR], 1.37; 95% CI, 1.14 to 1.66; mC, 0.55), but mainly f

112 vely, a substantial improvement was seen (IQ-OR, 1.64; 95% CI, 1.36 to 1.97; mC, 0.60).

113 3.99 [95% CI, 1.10 to 14.40]) and kanamycin (OR, 5.47 [95% CI, 1.64 to 18.24]) resistance was also si

114 s (OR, 0.89; 95% CI, 0.86-0.92) and Latinos (OR, 0.83; 95% CI, 0.81-0.86) had lower odds of filling a

115 0), or to have read the information leaflet (OR, 0.18; 95% CI: 0.08, 0.41).

116 dds of GERD, while higher educational level (OR = 0.53, 95%CI = 0.36,0.77) and regular physical activ

117 dds of GERD, while higher educational level (OR = 0.55, 95%CI = 0.33, 0.91) was associated with decre

118 (OR = 18.5, P < .0001), fluid-filled lumen (OR = 0.34, P = .002), and appendicolith (OR = 1.67, P =

119 (OR = 0.19, 95% CI 0.11-0.32) and lymphoma (OR = 0.18, 95% CI 0.11-0.28).

120 In univariate analysis, being married (OR = 1.57, 95%CI = 1.04, 2.36), general obesity (OR = 1.

121 ed evidence of a protective effect of masks (OR = 0.13; 95% CI: 0.03-0.62) and respirators (OR = 0.12

122 consumption of citrus fruits between meals (OR = 1.69, 95%CI = 1.04, 2.73) were associated with high

123 consumption of citrus fruits between meals (OR = 2.22, 95%CI = 1.30, 3.81) were positively associate

124 T-D use was 79.9% (range, 26.7%-100%; median OR, 2.08; 95% CI, 1.99-2.18).

125 phy nonattendees were less likely to be men (OR, 0.36; 95% CI: 0.18, 0.71), retired (OR, 0.31; 95% CI

126 ere were 21 cases of thyroid disease in men [OR=0.69 (95% CI: 0.33); 1.44 for an IQR increase (0.75 n

127 reased diagnostic performance by microscopy (OR 1.6, 95% CI 1.3-2.0, p<0.0001).

128 th diabetes but without DR, those with mild (OR, 1.81; 95% CI, 1.23-2.67; P = .003) and moderate (OR,

129 to mention screening-related anxiety (mild: OR, 6.30; 95% CI: 2.48, 15.97; moderate or severe: OR, 3

130 VA <20/200 in the multiple regression model (OR, 4.35; P = 0.011).

131 asible analysis of IPD (unstratified model) (OR, 0.1; 95% CI, 0.0-0.4).

132 ; 95% CI, 1.23-2.67; P = .003) and moderate (OR, 1.89; 95% CI, 1.16-3.07; P = .01) nonproliferative D

133 OR 1.29; 95% CI 1.03-1.62) and visible mold (OR 1.28; 95% CI 1.04-1.58) were associated with rhinitis

134 kly: OR = 0.64, 95% CI: 0.47, 0.85; monthly: OR = 0.60, 95% CI: 0.44, 0.81; yearly: OR = 0.58, 95% CI

135 ), needing assistance for at least 3 months (OR = 0.79; CI, 0.62-1.00), and proxy needed to fill out

136 ampicin-isoniazid regimens of 3 to 4 months (OR, 0.53 [CrI, 0.36 to 0.78]), rifampicin-isoniazid-pyra

137 al {CrI}, 0.50 to 0.83]) or 12 to 72 months (OR, 0.50 [CrI, 0.41 to 0.62]), rifampicin-only regimens

138 3-236.3) and maternal in-hospital mortality (OR, 79.1; 95% CI, 23.9-261.8).

139 acebo for reduction of short-term mortality (OR 0.65, 95% CI 0.41-1.05), whereas only low-quality evi

140 C2 independently predicted 90-day mortality (ORs 2.6, 95%CI = 1.3-6.4; and 2.4, 95%CI = 1.3-4.5, resp

141 ide over placebo to reduce mortality, and no ORs for any of the comparisons versus placebo were signi

142 .69), multinodular goiter or thyroid nodule (OR, 1.82; 95% CI, 1.01-3.28), and parathyroid lesion in

143 In the adjusted model, central obesity (OR = 1.88, 95%CI = 1.18, 3.01) and consumption of citrus

144 1.77, 95%CI = 1.11, 2.81), central obesity (OR = 2.09, 95%CI = 1.46,3.01) and consumption of citrus

145 terval [CI]: 3.69-9.55) and central obesity (OR = 3.45, 95% CI: 2.27-5.23) were strongly associated w

146 1.57, 95%CI = 1.04, 2.36), general obesity (OR = 1.77, 95%CI = 1.11, 2.81), central obesity (OR = 2.

147 General obesity (OR = 5.94, 95% confidence interval [CI]: 3.69-9.55) and

148 n was associated with overweight or obesity (OR: 1.57; 95% CI: 1.15, 2.13) and central overweight or

149 15, 2.13) and central overweight or obesity (OR: 1.73; 95% CI: 1.19, 2.50).

150 oline significantly associated with obesity (OR = 1.57; 95%CI 1.45-1.69, P = 3.84 x 10(-31)) and seru

151 per pack-year) and positively with obesity: OR: 1.97 [1.22-3.16], history of atopic disease (hay fev

152 CI 1.08-1.59), while exposure to mold odor (OR 1.29; 95% CI 1.03-1.62) and visible mold (OR 1.28; 95

153 Perception of OR safety of surgical practice was associated with hospi

154 associated with ever use of organochlorine [OR=2.7 (95% CI: 1.8, 4.0)] and organophosphate [OR=2.0 (

155 2.7 (95% CI: 1.8, 4.0)] and organophosphate [OR=2.0 (95% CI: 1.3, 3.0)] insecticides and phenoxyaceta

156 PATIENTS OR Trauma patients with injury severity scores greater t

157 BMI was associated with a lower risk of PD (OR 0.82, 95% CI 0.69-0.98).

158 5% confidence interval, CI, 0.40-0.66), PEH (OR=0.70, 95% CI 0.53-0.91), and PPU (OR=0.85, 95% CI 0.7

159 37), and after applying a 3-year lag period (OR, 1.09 per procedure; 95% CI, 1.03-1.14 and OR when ex

160 ications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high pr

161 "human" AND "dihydroartemisinin-piperaquine" OR "DHA-PPQ".

162 95% CI, 0.37 to 0.86; P = .007) and placebo (OR, 0.58; 95% CI, 0.37 to 0.93; P = .023) arms.

163 racotomy was not associated with 30-day POM (OR 0.97; 95% CI 0.51-1.84; P = 0.926).

164 ases for relevant RCTs and calculated pooled OR for 3-month mortality (safety outcome) and 3-month de

165 tors were significant when we matched pooled ORs with adult male smoking prevalence (z = 2.55, p = 0.

166 parathyroid lesion in the inferior position (OR, 6.82; 95% CI, 3.10-14.99) were independently associa

167 period following an SSO event, with positive ORs for all age groups and for three of the four countie

168 ), PEH (OR=0.70, 95% CI 0.53-0.91), and PPU (OR=0.85, 95% CI 0.7-0.95).

169 95% CI 1.45-4.62), and ergonomic practices (OR=1.67, 95% CI 1.04-2.67).

170 hile high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater len

171 -associated CS but 50% decreased prevalence (OR 0.54) of thyroid cancer compared to SDHx-associated C

172 ations confer a 2-fold increased prevalence (OR 2.7) of thyroid cancer compared to PTEN-associated CS

173 95 % CI 1.3-7.3; p=0.01) or being in prison (OR 2.3, 1.4-3.7; p=0.0007).

174 tile) and reference TL level (1st quintile) (OR = 2.68; 95% CI: 1.06, 6.79; p = 0.04 for BC-by-CRP-in

175 viduals with longer blood TL (5th quintile) (OR = 3.23; 95% CI: 1.37, 7.59; p = 0.04 for BC-by-TL-int

176 fidence interval [CI], 1.2-2.7), black race (OR, 1.5; 95% CI, 1.1-2.0), support with >/=inotropes at

177 7.7%) eye developed new vessels, odds ratio (OR) 0.12 [95% confidence interval (CI): 0.01, 1.03].

178 was associated with 30-day POM [odds ratio (OR) 1.71; 95% confidence interval (CI) 1.05-2.77); P = 0

179 odds of improving SMR over time [odds ratio (OR) 1.73; 95% confidence interval (CI) 1.03-2.91; P = 0.

180 quartile (4th) vs. lowest (1st), odds ratio (OR) = 0.66, 95% confidence interval (CI): 0.45, 0.98; P

181 rth quartile vs. first quartile, odds ratio (OR) = 2.70, 95% confidence interval (CI): 1.55, 4.70) an

182 production, predisposes to SLE (odds ratio (OR) = 3.47 in Asians (Pmeta = 3.1 x 10(-104)), OR = 2.61

183 The overall odds ratio (OR) for ER visits for GI illness was 1.09 [95% confidenc

184 Odds ratio (OR) for predicting poor outcome or standardized mean dif

185 terval: 1.12-2.55), rs4680 COMT (odds ratio (OR): 1.40; confidence interval: 1.04-1.87), rs5569 SLC6A

186 5; rs4662344-T: P=1.9 x 10(-18), odds ratio (OR)=1.23) and COLQ (collagen-like tail subunit of asymme

187 ndividuals who did not have ASD (odds ratio (OR)=22.33, 95% confidence interval (CI): 21.77-22.92).

188 decreased alloimmunization risk (odds ratio [OR] 0.26, 95% confidence [CI] 0.11-0.64).

189 rasitemic compared to AA adults (odds ratio [OR] 0.50 95% confidence interval [CI] 0.31-0.79, P = 0.0

190 ome were short disease duration (odds ratio [OR] 0.64, 95% CI 0.41-0.997 per year; p=0.048) and low b

191 onger total duration of uveitis (odds ratio [OR] 1.13, P < .001), bilateral uveitis (OR 3.51, P = .00

192 culosis diagnosis by microscopy (odds ratio [OR] 1.6, 95% CI 1.3-1.9, p<0.0001) or culture (1.7, 1.2-

193 or allele frequency [MAF] 0.22%; odds ratio [OR] 2.02; 95% CI 0.73-5.60; P = 0.18).

194 sure-lowering medicine (adjusted odds ratio [OR] 2.23, 95% CI 1.59-3.12); p<0.0001), combination ther

195 45] vs no-LD, 26.2% [11 of 42]; odds ratio [OR] = 0.062; confidence interval [CI], 0.011-0.361; p =

196 stoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P =

197 ere longer duration of symptoms (odds ratio [OR] = 1.46, P < .0001), increased maximum diameter (OR =

198 ds of ONHD presence by 1.5-fold (odds ratio [OR] = 1.56 [confidence interval (CI), 1.22-2.00]; P < 0.

199 ched to their primary caregiver (odds ratio [OR] = 1.7, p = 0.029, 95% CI [1.06, 2.76], d = 0.29).

200 lue were coma (31% had seizures; odds ratio [OR] = 1.8, p < 0.01) and history of seizures, either rem

201 likely to report skin clearance (odds ratio [OR], 0.20; 95% CI, 0.07-0.55) and more likely to use ste

202 adherent in both the tamoxifen (odds ratio [OR], 0.57; 95% CI, 0.37 to 0.86; P = .007) and placebo (

203 isoniazid regimens of 6 months (odds ratio [OR], 0.65 [95% credible interval {CrI}, 0.50 to 0.83]) o

204 cs had lower 30-day ACS-related (odds ratio [OR], 0.71; 95% CI, 0.50-1.00) and all-cause (OR, 0.50; 9

205 nd overall prostate cancer risk (odds ratio [OR], 1.03; 95% CI, 0.90 to 1.17).

206 endently associated with cancer (odds ratio [OR], 1.08 per procedure; 95% CI, 1.04-1.13).

207 her per 10-year increase in age (odds ratio [OR], 1.44; 95% confidence interval [CI], 1.20-1.72; P <

208 violence in the validation set (odds ratio [OR], 1.47 [95% CI, 1.23 to 1.79]); this association rema

209 exposed offspring (preterm birth odds ratio [OR], 1.47 [95% CI, 1.40-1.55]; small for gestational age

210 r NAFLD activity score (adjusted odds ratio [OR], 1.644; P = 0.021), whereas elevated creatinine leve

211 ous Australians, increasing age (odds ratio [OR], 1.72 per decade) and having not had an eye examinat

212 ear post-HT: >/=18 years of age (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.2-2.7), black

213 s associated with elevated SUVR (odds ratio [OR], 2.06; 95% CI, 1.16-3.65).

214 nt impact on hospital mortality (odds ratio [OR], 2.1; P = 0.1; OR, 5, P = 0.05, respectively).

215 olely associated with pattern 1 (odds ratio [OR], 3.3; 95% CI, 1.5-7.2), rhinitis with patterns 1 to

216 rovement were the LdT treatment (odds ratio [OR], 3.97 (1.37-11.5), p = 0.01) and pre-treated eGFR (O

217 id lesion size of 10 mm or less (odds ratio [OR], 4.37; 95% CI, 2.24-8.54), multigland disease (OR, 7

218 Ischemic heart disease (odds ratio [OR], 7.21; P < 0.001) and greater age (OR, 1.05; P = 0.0

219 red to non-use (14.3% vs. 33.3%; odds ratio [OR]: 0.33, 95% confidence interval [CI]: 0.114-0.978).

220 atively with cumulative smoking (odds ratio [OR]: 0.992; 95% CI 0.984-1.000 per pack-year) and positi

221 back pain among female subjects (odds ratio [OR]: 1.75, 95% confidence interval [CI]: 1.08-2.83, P-va

222 rotect against clinical malaria (odds ratio [OR]=0.95, 95% CI 0.68-1.32, p=0.745 for case-control ana

223 e organizational safety climate (Odds Ratio [OR]=2.76, 95% Confidence Interval [CI] 1.51-5.03), peopl

224 ay and 90-day mortality from EP (odds ratio, OR 0.51, 95% confidence interval, CI, 0.40-0.66), PEH (O

225 isk of bladder cancer [adjusted odds ratios (OR) = 3.90, 95% confidence interval (CI) = 2.65-5.73].

226 gher than lower estradiol, with odds ratios (OR) for asthma ranging from 1.25 for PFOS (95% Confidenc

227 The odds ratios (OR) of the prevalence of asymptomatic ICAS between the f

228 or multiple primary melanoma); odds ratios (ORs) and 95% CIs are reported.

229 We estimated odds ratios (ORs) and 95% confidence intervals (CIs) by logistic regr

230 s was used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs).

231 ion was used to obtain adjusted odds ratios (ORs) and adjusted rate differences with 95% confidence i

232 atient level to obtain adjusted odds ratios (ORs) and to control possible confounding effects among v

233 meta-analyses and expressed as odds ratios (ORs) or beta-estimates with 95% confidence interval (CI)

234 on models were used to estimate odds ratios (ORs) that were adjusted for comorbidity, education level

235 We calculated pooled odds ratios (ORs) using a random-effects model.

236 ontrast-enhanced (DCE) imaging, odds ratios (ORs) were calculated as the ratio of odds of cancer of t

237 Adjusted odds ratios (ORs) were calculated for each cohort and in a combined a

238 Effect sizes were reported as odds ratios (ORs) with 95% CIs.

239 Odds ratios (ORs) with 95% confidence intervals (CIs) for filling an

240 1.01-1.62) and increased 30-day readmission (OR, 1.30; 95% CI 1.04-1.62) following CEA.

241 ermined which medication a patient received (OR = 3.13; p = 3 x 10(-37)).

242 s and each expresses one olfactory receptor (OR) gene from a pool of over 1000.

243 ansions in the numbers of odorant receptors (ORs) and antennal lobe glomeruli.

244 I, 0.41 to 0.62]), rifampicin-only regimens (OR, 0.41 [CrI, 0.19 to 0.85]), rifampicin-isoniazid regi

245 rifampicin-isoniazid-pyrazinamide regimens (OR, 0.35 [CrI, 0.19 to 0.61]), and rifampicin-pyrazinami

246 .61]), and rifampicin-pyrazinamide regimens (OR, 0.53 [CrI, 0.33 to 0.84]) were efficacious compared

247 1.0-2.2), and treatment for early rejection (OR, 2.0; 95% CI, 1.5-2.7).

248 , 1.23 to 1.79]); this association remained (OR, 1.44 [CI, 1.20 to 1.76]) after adjustment for reason

249 es with data from 1976 through 1998 reported ORs ranging from 0.6 to 0.7 (n > 7121).

250 = 0.13; 95% CI: 0.03-0.62) and respirators (OR = 0.12; 95% CI: 0.06-0.26) against severe acute respi

251 men (OR, 0.36; 95% CI: 0.18, 0.71), retired (OR, 0.31; 95% CI: 0.13, 0.75), to report regular physica

252 ma (OR 1.80; 95% CI 1.27-2.55) and rhinitis (OR 1.41; 95% CI 1.03-1.93).

253 ere both associated with increased CRC risk [OR: 1.48 (95% CI: 1.08, 2.02) and OR: 1.50 (95% CI: 1.10

254 y of surgical practice among operating room (OR) personnel is associated with hospital-level 30-day p

255 The other (chromosome 17, rs1531554, OR = 0.68, P = 2.9 x 10(-8)) was replicated among female

256 d a strong independent association with RTT (OR, 1.46; 95% CI, 4.45-6.43; P < .001), with one of the

257 7, 7.04), erroneous beliefs about screening (OR, 32.15; 95% CI: 6.26, 165.19), or having undergone a

258 ing was associated with higher odds of SDCS (OR = 1.49, 95% CI: 1.21, 1.83) than was not having sex o

259 pared with those born via caesarean section (OR = 0.17, 95% CI: 0.06, 0.43 vs. OR = 0.65, 95% CI: 0.3

260 related to acute illness (34% had seizures; OR = 3.0, p < 0.001).

261 30; 95% CI: 2.48, 15.97; moderate or severe: OR, 3.63; 95% CI: 1.87, 7.04), erroneous beliefs about s

262 in-chain and chain-end incorporation of -Si(OR)3 groups whose ratios depend on temperature and ethyl

263 83, 95% CI: 1.18, 6.75) and current smokers (OR = 1.30, 95% CI: 0.69, 2.44) for IL-8.

264 erval (CI): 1.55, 4.70) and current smokers (OR = 1.99, 95% CI: 1.15, 3.44) for IL-6 and among former

265 15, 3.44) for IL-6 and among former smokers (OR = 2.83, 95% CI: 1.18, 6.75) and current smokers (OR =

266 nt consultation with a fertility specialist (OR, 29.96; 95% CI, 2.48 to 361.41; P = .007), parent rec

267 o 75.94; P = .007), and higher Tanner stage (OR, 5.42; 95% CI, 1.75 to 16.78; P = .003) were associat

268 rgeries, including prolonged length of stay (OR, 1.37; 95% CI, 1.11-1.70) following OAR as well as hi

269 0.07-0.55) and more likely to use steroids (OR, 5.04; 95% CI, 1.91-13.31).

270 d with increased risk of basal-like subtype [OR 4.17; 95% confidence interval (CI) 1.89-9.21] compare

271 her likelihood of complete clinical success (OR 0.95 per extra year, 0.93-0.98; p<0.001) and clinical

272 f walking capacity at 4 weeks after surgery [OR 0.77 (95% CI 0.30-1.97)].

273 0), and proxy needed to fill out the survey (OR = 0.72; CI, 0.61-0.85) were associated with lower odd

274 higher incidence of the metabolic syndrome (OR=2.49; 95% CI 1.30-4.77), a steeper increase of waist

275 eases, including primary Sjogren's syndrome (OR = 2.45 in Chinese, OR = 2.35 in European Americans) a

276 = .01), and presence of posterior synechiae (OR 3.28, P = .004).

277 similarly prevalent in the highest tertile (OR = 0.92, 95% CI = 0.73-1.16, p = 0.49) when compared w

278 cantly more prevalent in the lowest tertile (OR = 1.58, 95% CI = 1.29-1.94, p < 0.001) and similarly

279 undergone a recent fecal occult blood test (OR, 13.69; 95% CI: 3.66, 51.29).

280 In Arabidopsis (Arabidopsis thaliana), OR increases carotenoid levels by posttranscriptionally

281 (5.14, P < 0.001), whereas for 8q gain, the OR was highest for ciliary body location (102.87, P = 0.

282 For chromosome 8p loss, the OR was highest for ciliary body location (53.91, P = 0.0

283 t significantly different between therapies (OR: 1.22; 95% CI: 0.94 to 1.59).

284 -4.35]; I2 = 2%), renal replacement therapy (OR, 1.90 [95% CI, 1.25-2.90]; I2 = 17%), and death (OR,

285 -20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a

286 reatment and standard BP-lowering treatment (OR: 0.99; 95% CI: 0.82 to 1.20, p=0.909).

287 oniazid regimens compared with no treatment (OR, 0.36 [CrI, 0.18 to 0.73]).

288 dency risk compared with standard treatment (OR: 0.91; 95% CI: 0.80 to 1.02), p=0.106).

289 with increased susceptibility to CD and UC (OR: 2.12; 95% CI: 1.33, 3.36 and OR: 1.61; 95% CI: 1.01,

290 Immunological mechanisms underlying OR differ according to the type of exposure.

291 to report topical calcineurin inhibitor use (OR, 0.16; 95% CI, 0.06-0.42), and among all patients tha

292 tio [OR] 1.13, P < .001), bilateral uveitis (OR 3.51, P = .009), low visual acuity (OR 5.1, P = .001)

293 .1, P = .001), high laser-flare (LF) values (OR 1.74, P = .01), and presence of posterior synechiae (

294 n section (OR = 0.17, 95% CI: 0.06, 0.43 vs. OR = 0.65, 95% CI: 0.31, 1.35, respectively, interaction

295 children (OR = 0.30, 95% CI: 0.15, 0.61 vs. OR = 0.78, 95% CI: 0.29, 2.11, respectively, interaction

296 ) and regular physical activity >/=2 h/week (OR = 0.53, 95%CI = 0.30, 0.94) were associated with lowe

297 associated with lower odds of SDCS (weekly: OR = 0.64, 95% CI: 0.47, 0.85; monthly: OR = 0.60, 95% C

298 to have stopped all other treatment as well (OR, 0.45; 95% CI, 0.26-0.76).

299 ic race/ethnicity versus non-Hispanic White (OR 1.10, 95% confidence interval (CI) 1.05-1.16), and ca

300 lifetime days of use for 16 pesticides with OR>/=1.2 for ever use.

301 had an eye examination within the past year (OR, 1.61) were risk factors for vision loss.

302 thly: OR = 0.60, 95% CI: 0.44, 0.81; yearly: OR = 0.58, 95% CI: 0.39, 0.85) versus discontinued commu